359 results on '"Diallo, Jean-Simon"'
Search Results
2. Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
3. High throughput screen identifies lysosomal acid phosphatase 2 (ACP2) to regulate IFN-1 responses to potentiate oncolytic VSV∆51 activity
4. Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy
5. Immune profiling of dedifferentiated liposarcoma and identification of novel antigens for targeted immunotherapy
6. Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
7. A cyclic lipopeptide from Fusarium graminearum targets plant membranes to promote virulence
8. Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy
9. Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials
10. A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infection
11. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy
12. Optimal delivery of RNA interference by viral vectors for cancer therapy
13. Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen
14. Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy
15. Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
16. Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy
17. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry
18. SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition
19. Combining vanadyl sulfate with Newcastle disease virus potentiates rapid innate immune-mediated regression with curative potential in murine cancer models
20. Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
21. Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation
22. Development of a novel screening platform for the identification of small molecule inhibitors of human adenovirus
23. Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies
24. Enhancement of oncolytic virotherapy by vanadium(V) dipicolinates
25. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds
26. The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
27. An In Silico Database for Automated Feature Identification of High-Resolution Tandem Mass Spectrometry 13C Trimethylation Enhancement Using Diazomethane (13CTrEnDi)- Modified Lipid Data
28. Overcoming the challenge of antiviral defense in viral vector manufacturing
29. Single-particle characterization of oncolytic vaccinia virus by flow virometry
30. Oncolytic vesicular stomatitis virus expressing interferon-σ has enhanced therapeutic activity
31. Contributors
32. Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges
33. Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications.
34. Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer Immunotherapy
35. Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus
36. Data from Customized Viral Immunotherapy for HPV-Associated Cancer
37. Supplementary figures 1-7 from Customized Viral Immunotherapy for HPV-Associated Cancer
38. Supplementary Figure Legends from Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
39. Supplementary Figure S7 from Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
40. Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
41. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection
42. CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOX
43. Combining povidone‐iodine with vancomycin can be beneficial in reducing early biofilm formation of methicillin‐resistant Staphylococcus aureus and methicillin‐sensitive S. aureus on titanium surface
44. A Fungal Ionophore Toxin Activates Plant Inducible Immune Signaling to Promote Susceptibility
45. Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition
46. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
47. SnapShot: Cancer Immunotherapy with Oncolytic Viruses
48. Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
49. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
50. HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.